Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

2.

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Pyles RB, Baum MM, Moss JA.

Open Virol J. 2018 Feb 28;12:1-13. doi: 10.2174/1874357901812010001. eCollection 2018.

3.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles RB, Marzinke MA, Moss JA, Baum MM.

PLoS One. 2017 Sep 7;12(9):e0184303. doi: 10.1371/journal.pone.0184303. eCollection 2017.

4.

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.

Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay PA.

PLoS One. 2016 Jul 21;11(7):e0159511. doi: 10.1371/journal.pone.0159511. eCollection 2016.

5.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

6.

C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, Gallay PA.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):693-8. doi: 10.1128/AAC.01925-15. Print 2016 Jan.

7.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

8.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

9.

The role of immunophilins in viral infection.

Hopkins S, Gallay PA.

Biochim Biophys Acta. 2015 Oct;1850(10):2103-10. doi: 10.1016/j.bbagen.2014.11.011. Epub 2014 Nov 18.

10.

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Lim PJ, Gallay PA.

Curr Opin Virol. 2014 Oct;8:30-7. doi: 10.1016/j.coviro.2014.04.012. Epub 2014 May 27. Review.

11.

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA.

Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14. Epub 2014 Mar 31.

12.

HCV core protein and virus assembly: what we know without structures.

Gawlik K, Gallay PA.

Immunol Res. 2014 Oct;60(1):1-10. doi: 10.1007/s12026-014-8494-3. Review.

PMID:
24557493
13.

HCV core residues critical for infectivity are also involved in core-NS5A complex formation.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA.

PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.

14.

Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Baugh JM, Garcia-Rivera JA, Gallay PA.

Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30. Review.

15.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

16.

Profile of alisporivir and its potential in the treatment of hepatitis C.

Gallay PA, Lin K.

Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15. Review.

17.

Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication.

Garcia-Rivera JA, Lin K, Hopkins S, Gregory MA, Wilkinson B, Gallay PA.

Open Virol J. 2012;6:97-102. doi: 10.2174/1874357901206010097. Epub 2012 Nov 26.

18.

HCV NS5A and IRF9 compete for CypA binding.

Bobardt M, Hopkins S, Baugh J, Chatterji U, Hernandez F, Hiscott J, Sluder A, Lin K, Gallay PA.

J Hepatol. 2013 Jan;58(1):16-23. doi: 10.1016/j.jhep.2012.08.007. Epub 2012 Aug 15.

19.

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5113-21. doi: 10.1128/AAC.00919-12. Epub 2012 Jul 16.

20.

Correlation between NS5A dimerization and hepatitis C virus replication.

Lim PJ, Chatterji U, Cordek D, Sharma SD, Garcia-Rivera JA, Cameron CE, Lin K, Targett-Adams P, Gallay PA.

J Biol Chem. 2012 Aug 31;287(36):30861-73. doi: 10.1074/jbc.M112.376822. Epub 2012 Jul 16.

21.

Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.

Gunaseelan S, Gallay PA, Bobardt MD, Dezzutti CS, Esch T, Maskiewicz R.

Pharm Res. 2012 Nov;29(11):3156-68. doi: 10.1007/s11095-012-0811-8. Epub 2012 Jun 27. Erratum in: Pharm Res. 2013 Mar;30(3):911.

22.

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97. doi: 10.1128/AAC.00693-12. Epub 2012 May 14.

23.

Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.

Maskiewicz R, Bobardt M, Chatterji U, Gunaseelan S, Dezzutti CS, Penin F, Gallay PA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3336-43. doi: 10.1128/AAC.00186-12. Epub 2012 Mar 19.

24.

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.

Gallay PA.

Immunol Res. 2012 Jun;52(3):200-10. doi: 10.1007/s12026-011-8263-5. Review.

PMID:
22169996
25.

HSV neutralization by the microbicidal candidate C5A.

de Witte L, Bobardt MD, Chatterji U, van Loenen FB, Verjans GM, Geijtenbeek TB, Gallay PA.

PLoS One. 2011 May 6;6(5):e18917. doi: 10.1371/journal.pone.0018917.

26.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

27.

Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA.

Antimicrob Agents Chemother. 2010 Jul;54(7):2753-66. doi: 10.1128/AAC.01606-09. Epub 2010 May 3.

28.

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Chatterji U, Bobardt MD, Lim P, Gallay PA.

J Gen Virol. 2010 May;91(Pt 5):1189-93. doi: 10.1099/vir.0.018531-0. Epub 2010 Jan 27.

29.

Cyclophilin inhibitors.

Gallay PA.

Clin Liver Dis. 2009 Aug;13(3):403-17. doi: 10.1016/j.cld.2009.05.002. Review.

PMID:
19628157
30.

Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.

Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5525-30. doi: 10.1073/pnas.0801388105. Epub 2008 Mar 31.

31.

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. doi: 10.1073/pnas.0712380105. Epub 2008 Feb 19.

32.

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, de Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B.

Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17. doi: 10.1128/AAC.01324-07. Epub 2008 Jan 22.

33.

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells.

Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA.

J Virol. 2007 Jan;81(1):395-405. Epub 2006 Oct 18.

34.

Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.

Chatterji U, Bobardt MD, Gaskill P, Sheeter D, Fox H, Gallay PA.

J Biol Chem. 2006 Dec 1;281(48):37025-33. Epub 2006 Oct 6.

35.

Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins.

Saphire AC, Gallay PA, Bark SJ.

J Proteome Res. 2006 Mar;5(3):530-8. Erratum in: J Proteome Res. 2006 May;5(5):1279.

PMID:
16512667
36.

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.

Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, Jones MJ, Stoddart CA, Scalfaro P, Dumont JM, Besseghir K, Rosenwirth B, Gallay PA.

J Biol Chem. 2005 Dec 2;280(48):40293-300. Epub 2005 Sep 30.

37.

A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.

de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA.

J Biol Chem. 2005 Nov 25;280(47):39493-504. Epub 2005 Sep 12.

38.

Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex.

Galigniana MD, Morishima Y, Gallay PA, Pratt WB.

J Biol Chem. 2004 Dec 31;279(53):55754-9. Epub 2004 Oct 20.

39.

Effect of polyanion-resistance on HIV-1 infection.

Bobardt MD, Armand-Ugón M, Clotet I, Zhang Z, David G, Este JA, Gallay PA.

Virology. 2004 Aug 1;325(2):389-98.

40.

Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion.

Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA.

J Virol. 2004 Jun;78(12):6567-84.

41.

Syndecan captures, protects, and transmits HIV to T lymphocytes.

Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA.

Immunity. 2003 Jan;18(1):27-39.

44.

Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.

Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA.

J Virol. 2001 Oct;75(19):9187-200.

45.

Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells.

Saphire AC, Bobardt MD, Gallay PA.

Immunol Res. 2000;21(2-3):211-7. Review.

PMID:
10852119
46.

Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.

Saphire AC, Bobardt MD, Gallay PA.

EMBO J. 1999 Dec 1;18(23):6771-85.

Supplemental Content

Loading ...
Support Center